Significant investment will enable world-class
discovery research, innovation in data science and digital health
and collaborations in the Bay Area
Johnson & Johnson (NYSE: JNJ) (the Company) today opened its
San Francisco Bay Campus, a state-of-the-art Research &
Development (R&D) facility in the Bay Area, one of the world’s
most established global hubs for innovation and entrepreneurship.
The nearly 200,000 square-foot facility will house up to 400
employees, more than doubling the R&D presence of Johnson &
Johnson in the Bay Area. The campus bridges key scientific and
technological capabilities by co-locating Janssen R&D, Johnson
& Johnson Innovation and Johnson & Johnson Technology. It
will further integrate the Company into the Bay Area innovation
ecosystem to strengthen and increase collaborations with innovators
to accelerate growth.
“Johnson & Johnson’s expanded presence in the Bay Area
affirms our commitment to combining science and technology to
deliver transformative healthcare solutions,” said Joaquin Duato,
Chief Executive Officer, Johnson & Johnson. “On this campus,
our talented teams will use their diverse experience and expertise
to tackle society’s greatest health challenges to create a better
future for patients.”
The R&D focus at the new site spans Janssen’s therapeutic
areas and key functions, including emerging science and
technologies for gene and RNA therapies, novel treatments and
approaches for retinal and infectious diseases, and advanced data
science, including artificial intelligence and machine learning.
Co-locating expertise at the site will enable the expansion of the
Company’s world-class discovery engine and industry-leading
pipeline.
“Our new state-of-the-art science facility in the Bay Area will
further strengthen our R&D capabilities and transform how we
discover, develop and deliver innovative medicines faster and more
efficiently. By integrating drug discovery, data science and
digital health, we aim to accelerate the growth of our
best-in-class portfolio and deliver better health outcomes for
people worldwide,” said James Merson, Ph.D., Site Head, San
Francisco Bay Campus and Global Therapeutic Area Head, Infectious
Diseases, Janssen Research & Development, LLC.
The Johnson & Johnson Innovation Center in California has
facilitated investments and collaborations to accelerate
early-stage healthcare innovation with academic and industry
partners in the Bay Area and greater California ecosystem since
2014. The San Francisco Bay Campus, along with the Company’s JLABS
@ South San Francisco, will continue to enable the Company to build
strong relationships with entrepreneurs, scientists and investors
to support and invest in highly differentiated innovations that
extend and improve lives everywhere. Additionally, given the
convergence of healthcare and technology in the region, the Company
will increase its focus on the Johnson & Johnson Technology
organization to enhance its ability to create innovative digital
solutions to advance human health.
Building on Johnson & Johnson’s long-standing commitment to
use its expertise and resources to reduce the environmental
footprint of its operations, the Bay Area hub is designed as a
high-performance green campus, reinforcing the Company’s pledge to
be responsible stewards in creating a healthy, more sustainable
future. The aim is for the new site to receive Silver Leadership in
Energy & Environmental Design (LEED) certification, the most
widely used green building rating system in the world.
About Johnson & Johnson At Johnson & Johnson, we
believe good health is the foundation of vibrant lives, thriving
communities and forward progress. That’s why for more than 135
years, we have aimed to keep people well at every age and every
stage of life. Today, as the world’s largest and most broadly-based
healthcare company, we are committed to using our reach and size
for good. We strive to improve access and affordability, create
healthier communities, and put a healthy mind, body and environment
within reach of everyone, everywhere. We are blending our heart,
science and ingenuity to profoundly change the trajectory of health
for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.
About the Janssen Pharmaceutical Companies of Johnson &
Johnson At Janssen, we're creating a future where disease is a
thing of the past. We're the Pharmaceutical Companies of Johnson
& Johnson, working tirelessly to make that future a reality for
patients everywhere by fighting sickness with science, improving
access with ingenuity, and healing hopelessness with heart. We
focus on areas of medicine where we can make the biggest
difference: Cardiovascular, Metabolism & Retina; Immunology;
Infectious Diseases & Vaccines; Neuroscience; Oncology; and
Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at
@JanssenGlobal. Janssen Research & Development, LLC is part of
the Janssen Pharmaceutical Companies of Johnson & Johnson.
About Johnson & Johnson Innovation Johnson &
Johnson Innovation LLC works across the pharmaceutical, medical
device and consumer health sectors to accelerate early-stage,
transformational solutions by catalyzing the best ideas, wherever
they are in the world. We do this by harnessing our deep scientific
capabilities coupled with a wide range of tools, including
customized deal structures, company creation, incubation and
startup services, capital investments and other innovative business
models that aim to meet the diverse needs of entrepreneurs,
scientists, and emerging companies. Our goal is to help life
science and health technology innovations thrive through
collaboration and partnership with the global ecosystem, so that
together we can change the trajectory of human health. Meet our
passionate team of science and technology experts and learn how to
collaborate with us at www.jnjinnovation.com.
About Johnson & Johnson Technology Johnson &
Johnson Technology solves big problems in healthcare through
technology and digital innovation. Just as doctors use scalpels, we
use data science, algorithms, artificial intelligence, robotics,
and other digital solutions to transform patients’ lives. From
guiding patients through treatment to accelerating vaccine
development to enabling employees to work seamlessly from any
location, our digital tools infuse our products with novelty,
dexterity, and ease. Guided by Our Credo, we unleash the power of
technology for good to drive greater access, equity, and
sustainability, and to shape the future of healthcare in the way
that only we can.
Cautions Concerning Forward-Looking Statements This press
release contains “forward-looking statements” as defined in the
Private Securities Litigation Reform Act of 1995 regarding, among
other things: future operating and financial performance, product
development, market position and business strategy. The reader is
cautioned not to rely on these forward-looking statements. These
statements are based on current expectations of future events. If
underlying assumptions prove inaccurate or known or unknown risks
or uncertainties materialize, actual results could vary materially
from the expectations and projections of Janssen Research &
Development, LLC. Risks and uncertainties include, but are not
limited to: economic factors, such as interest rate and currency
exchange rate fluctuations; competition, including technological
advances, new products and patents attained by competitors;
challenges inherent in new product research and development,
including uncertainty of clinical success and obtaining regulatory
approvals; uncertainty of commercial success for new and existing
products; challenges to patents; the impact of patent expirations;
the ability of the Company to successfully execute strategic plans;
the impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain;
product efficacy or safety concerns resulting in product recalls or
regulatory action; significant adverse litigation or government
action, including related to product liability claims; changes to
applicable laws and regulations, including tax laws and global
healthcare reforms; trends toward healthcare cost containment;
changes in behavior and spending patterns of purchasers of
healthcare products and services; financial instability of
international economies and legal systems and sovereign risk;
increased scrutiny of the healthcare industry by government
agencies; the Company's ability to satisfy the necessary conditions
to consummate the separation of the Company's Consumer Health
business on a timely basis or at all; the Company's ability to
successfully separate the Company's Consumer Health business and
realize the anticipated benefits from the separation; the New
Consumer Health Company's ability to succeed as a standalone
publicly traded company; and risks related to the impact of the
COVID-19 global pandemic, such as the scope and duration of the
outbreak, government actions and restrictive measures implemented
in response, material delays and cancellations of medical
procedures, supply chain disruptions and other impacts to the
business, or on the Company’s ability to execute business
continuity plans as a result of the COVID-19 pandemic. A further
list and descriptions of these risks, uncertainties and other
factors can be found in Johnson & Johnson's Annual Report on
Form 10-K for the fiscal year ended January 2, 2022, including in
the sections captioned “Cautionary Note Regarding Forward-Looking
Statements” and “Item 1A. Risk Factors,” and in Johnson &
Johnson's subsequent Quarterly Reports on Form 10-Q and other
filings with the Securities and Exchange Commission. Copies of
these filings are available online at www.sec.gov, www.jnj.com or
on request from Johnson & Johnson. Any forward-looking
statement made in this release speaks only as of the date of this
release. Johnson & Johnson does not undertake to update any
forward-looking statement as a result of new information or future
events or developments.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220920005339/en/
Media: Jake Sargent +1 732-524-1090
JSargen3@its.jnj.com
Rachael Jarnagin + 1 415-705-9023 RJarnagi@its.jnj.com
Investor Relations: Raychel Kruper +1 732-524-6164
RKruper@its.jnj.com
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024